NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer

Confirmed Complete Response and Two Partial Responses Achieved in Heavily Pre-treated Population Patients had Median of Five Prior Lines of Therapy EDINBURGH, United Kingdom, March 10, 2020 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) announced preliminary results from part one of the Phase II study of single-agent Acelarin in patients […] Lire la suite »

Résultats annuels 2019 : Avancées significatives dans la NASH, la MPS VI et le psoriasis et visibilité financière étendue

 ►     Lanifibranor : Confirmation de la publication des résultats de l’étude clinique de Phase IIb NATIVE évaluant lanifibranor dans la NASH au S1 2020 suite à la finalisation du recrutement des patients  ►     Odiparcil : Publication des résultats positifs de l’étude clinique de Phase IIa iMProveS évaluant odiparcil dans la MPS VI […] Lire la suite »

Constellium Files Annual Report on Form 20-F

PARIS, March 10, 2020 (GLOBE NEWSWIRE) — Constellium SE (NYSE: CSTM) (“Constellium” or the “Company”) has filed its annual report on Form 20-F for the year ended December 31, 2019 with the U.S. Securities and Exchange Commission.  The 2019 20-F is available on Constellium’s website at https://www.constellium.com/investors and on the […] Lire la suite »